<DOC>
	<DOCNO>NCT01962415</DOCNO>
	<brief_summary>The objective study demonstrate efficacy use reduced-intensity condition regimen UCBT , double cord UCBT , match unrelated donor ( MUD ) bone marrow transplant ( BMT ) peripheral blood stem cell transplant ( PBSCT ) patient non-malignant disorder amenable treatment HSCT . After transplant , subject follow late effect ongoing graft success .</brief_summary>
	<brief_title>Reduced Intensity Conditioning Patients Aged ≤35 With Non-Malignant Disorders Undergoing UCBT , BMT , PBSCT</brief_title>
	<detailed_description>Hematopoietic stem cell transplantation ( HSCT ) curative therapy many pediatric malignant non-malignant disorder ( NMD ) , latter include primary immunodeficiency ( PID ) , hemoglobinopathy , inherit metabolic disorder , bone marrow failure syndrome . These NMD often significant morbidity risk premature mortality , HSCT curative either replacement defective hematopoietic cell healthy donor cell production deficient enzyme donor cell . HSCT patient NMD differs malignant disorder two important reasons- first , patient typically naïve chemotherapy immunosuppression potentially leading difficulty engraftment , second , absence malignancy , reduced-intensity conditioning ( RIC ) subsequent bone marrow chimerism may curative result decrease transplant-related mortality ( TRM ) . In research study , instead use standard myeloablative conditioning , study doctor use reduced-intensity conditioning ( RIC ) , low dos chemotherapy use . Although low dos may eradicate every single stem cell bone marrow , nevertheless present combination still intend eliminate already form immune cell , pave way successful engraftment donor cord blood cell . Engrafting cord blood cell outcompete reject patient ' survive stem cell . With reduced-intensity conditioning , side effect brain , heart , lung , liver , organ function usually less severe , patient well long-term recovery . There also realistic hope lower dos chemotherapy many patient avoid become sterile . The purpose study collect data patient undergoing reduced-intensity conditioning HSCT , study doctor compare standard myeloablative conditioning expectation full therapeutic benefit pair well survival rate improve quality life follow reduce intensity approach compare myeloablative regimen . The subject stratify accord type primary disease degree immune competence three stratum use different amount alemtuzumab prior transplant . Male female subject age 2 month 35 year ( inclusive ) meet eligibility criterion consider study . Non-malignant disease population amenable stem cell treatment , list eligibility section , consider appropriate study . A full list eligibility criterion appear later record .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Metabolic Diseases</mesh_term>
	<mesh_term>Pancytopenia</mesh_term>
	<mesh_term>Hemoglobinuria , Paroxysmal</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<mesh_term>Hydroxyurea</mesh_term>
	<mesh_term>Thiotepa</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>1 . Patient must 2 month 35 year ( inclusive ) age diagnosis . 2 . Patients must 4/6 , 5/6 6/6 HLA match related unrelated UCB unit available deliver precryopreservation total nucleate cell dose &gt; 3 x 107 cells/kg , double unit graft , cord blood unit deliver least 2x10e7 cells/kg . 3 . Patients must 8 8 7 8 HLA allele level match unrelated donor bone marrow peripheral blood progenitor graft 4 . Patient must adequate function organ system measure : 1 . Creatinine ≤ 2.0 mg/dl creatinine clearance ≥ 50 ml/min/1.73 m2 . 2 . Hepatic transaminase ( ALT/AST ) ≤ 4 x normal . 3 . Adequate cardiac function echocardiogram radionuclide scan ( shorten fraction &gt; 26 % ejection fraction &gt; 40 % &gt; 80 % normal value age ) . 4 . Pulmonary function test demonstrate CVC FEV1/FVC &gt; 50 % predict age and/or rest pulse oximeter ≥ 92 % room air clearance pediatric adult pulmonologist . For adult patient DLCO ( correct hemoglobin ) &gt; 50 % predict , DLCO obtain . 5 . Patient , parent , legal guardian must give write informed consent and/or assent accord FDA guideline . 6 . Patients may pregnant lactate must current negative pregnancy test pubertal and/or menstruating . 7 . Patients must minimum life expectancy least 6 month . 8 . Patients must HIV negative . 9 . Patients must uncontrolled infection time cytoreduction . 10 . Patients nonmalignant disorder amenable treatment stem cell transplantation , include limit : A . Primary Immunodeficiency syndrome include limited : Severe Combined Immune Deficiency ( SCID ) NK cell activity Omenn Syndrome Bare Lymphocyte Syndrome ( BLS ) Combined Immune Deficiency ( CID ) syndrome Combined Variable Immune Deficiency ( CVID ) syndrome WiskottAldrich Syndrome Leukocyte adhesion deficiency Chronic granulomatous disease ( CGD ) Xlinked Hyper IgM ( XHIM ) syndrome IPEX syndrome Chediak Higashi Syndrome Autoimmune Lymphoproliferative Syndrome ( ALPS ) Hemophagocytic Lymphohistiocytosis ( HLH ) syndromes Lymphocyte Signaling defect Other primary immune defect hematopoietic stem cell transplantation may beneficial B. Congenital bone marrow failure syndromes include limit : • Dyskeratosis Congenita ( DC ) Congenital Amegakaryocytic Thrombocytopenia ( CAMT ) Osteopetrosis C. Inherited Metabolic Disorders ( IMD ) include limited : Mucopolysaccharidoses Hurler syndrome ( MPS I ) Hunter syndrome ( MPS II ) Sanfilippo syndrome ( MPS II ) Leukodystrophies Krabbe Disease , also know globoid cell leukodystrophy Metachromatic leukodystrophy ( MLD ) Xlinked adrenoleukodystrophy ( ALD ) Other inherit metabolic disorder alpha mannosidosis Gaucher Disease Other inheritable metabolic disease hematopoietic stem cell transplantation may beneficial . D. Hereditary anemias • Thalassemia major • Sickle cell disease ( SCD ) • Diamond Blackfan Anemia ( DBA ) • congenital transfusion dependent anemia Patients sickle disease must one following : Overt silent stroke Pain crisis ≥ 2 episode per year past year One episodes acute chest syndrome Osteonecrosis involve ≥ 1 joint Priapism 1 . No suitable unrelated donor graft choice detail . 2 . Available HLAmatched relate live donor unaffected recipient 's disease able eligible donate without previous UCB donation . 3 . Allogeneic hematopoietic stem cell transplant within previous 6 month . 4 . Any active malignancy MDS . 5 . Severe acquire aplastic anemia . 7 . Uncontrolled bacterial , viral fungal infection ( currently take medication progression clinical symptom ) . 8 . Pregnancy nurse mother . 9 . HIV positive 10 . Poorly control pulmonary hypertension . 11 . Any condition preclude serial followup .</criteria>
	<gender>All</gender>
	<minimum_age>2 Months</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Severe Combined Immune Deficiency ( SCID ) NK cell activity</keyword>
	<keyword>Omenn Syndrome</keyword>
	<keyword>Bare Lymphocyte Syndrome ( BLS )</keyword>
	<keyword>Combined Immune Deficiency ( CID ) syndrome</keyword>
	<keyword>Combined Variable Immune Deficiency ( CVID ) syndrome</keyword>
	<keyword>Wiskott-Aldrich Syndrome</keyword>
	<keyword>Leukocyte adhesion deficiency</keyword>
	<keyword>Chronic granulomatous disease ( CGD )</keyword>
	<keyword>X-linked Hyper IgM ( XHIM ) syndrome</keyword>
	<keyword>IPEX syndrome</keyword>
	<keyword>Chediak -Higashi Syndrome</keyword>
	<keyword>Autoimmune Lymphoproliferative Syndrome ( ALPS )</keyword>
	<keyword>Hemophagocytic Lymphohistiocytosis ( HLH ) syndrome</keyword>
	<keyword>Lymphocyte Signaling defect</keyword>
	<keyword>Other primary immune defect HSCT may beneficial</keyword>
	<keyword>Dyskeratosis Congenita ( DC )</keyword>
	<keyword>Congenital Amegakaryocytic Thrombocytopenia ( CAMT )</keyword>
	<keyword>Osteopetrosis</keyword>
	<keyword>Mucopolysaccharidoses</keyword>
	<keyword>Hurler syndrome ( MPS I )</keyword>
	<keyword>Hunter syndrome ( MPS II )</keyword>
	<keyword>Sanfilippo syndrome ( MPS II )</keyword>
	<keyword>Leukodystrophies</keyword>
	<keyword>Krabbe Disease , also know globoid cell leukodystrophy</keyword>
	<keyword>Metachromatic leukodystrophy ( MLD )</keyword>
	<keyword>X-linked adrenoleukodystrophy ( ALD )</keyword>
	<keyword>Other inherit metabolic disorder</keyword>
	<keyword>alpha mannosidosis</keyword>
	<keyword>Other inheritable metabolic disease HSCT may beneficial .</keyword>
	<keyword>Thalassemia major</keyword>
	<keyword>Sickle cell disease ( SCD )</keyword>
	<keyword>Diamond Blackfan Anemia ( DBA )</keyword>
	<keyword>congenital transfusion dependent anemia</keyword>
	<keyword>Gaucher Disease</keyword>
</DOC>